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Resumen
Introducción: La polimixina B se ha aplicado como uno de los antibióticos de último recurso para el tratamiento de 
la multirresistencia entre las infecciones bacterianas Gram negativas. Debido a efectos secundarios como toxicidad 
renal, el uso de polimixina se asocia con limitaciones. El presente estudio evalúa la actividad antibacteriana in vitro 
de varios productos comerciales de polimixina B contra Pseudomonas aeruginosa.
Métodos: Este estudio incluyó 63 aislados de P. aeruginosa no duplicados que se examinaron para la prueba de sus-
ceptibilidad in vitro a la polimixina B utilizando los siguientes discos de polvo: sulfato de polimixina B, otosporina, 
Poly-Mxb y Myxacort. También se han identificado las MIC50 y MIC90 para los antibióticos de polimixina B.
Resultados: Myxacort tuvo una actividad funcional contra la mayoría de los aislados de P. aeruginosa, y sólo siete 
aislados tuvieron una CIM relativamente alta. Las actividades de Poly-MXb y Myxacort fueron las mismas que las de 
otosporina.
Conclusiones: Nuestros resultados revelaron que el producto genérico nacional de polimixina B (Myxacort), y dos 
productos externos (Otosporin, Poly-MXb) son similares en términos de actividad microbiológica.
Palabras clave: Pseudomonas aeruginosa; productos con polimixina B; método de microdilución en caldo.
Abstract
Introduction: Polymyxin B has been applied as one of the last-resort antibiotics for the treatment of multidrug 
resistance among Gram-negative bacterial infections. Due to side effects such as renal toxicity, the use of polymyxin 
is associated with limitations. The present study evaluates in vitro antibacterial activity of a number of polymyxin B 
commercial products against Pseudomonas aeruginosa.
Methods: This study included 63 non-duplicated P. aeruginosa isolates examined for in vitro polymyxin B suscepti-
bility testing using the following powder disks: polymyxin B sulfate, otosporin, Poly-Mxb, and Myxacort. MIC50 and 
MIC90 have also been identified for polymyxin B antibiotics.
Results: Myxacort had functional activity against most P. aeruginosa isolates, and only seven isolates had a relative-
ly high MIC. The activities of Poly-MXb and Myxacort were the same as otosporin.
Conclusions: Our findings revealed that the national generic polymyxin B product (Myxacort), and two external 
products (Otosporin, Poly-MXb) are similar in terms of microbiological activity.
Key words: Pseudomonas aeruginosa, Polymyxin B products, Broth microdilution method.
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Introduction
Pseudomonas aeruginosa has been recognized as an important opportunistic pathogen in clinical set-
tings and a major source of multidrug resistance(1). This bacterium causes high mortality in immuno-
compromised patients and has currently been known as a “superbug” owing to the limited effective-
ness of antimicrobial drugs(2). Infections due to multidrug-resistant (MDR) P. aeruginosa, in particular 
carbapenem-resistant isolates, are escalating in healthcare facilities and are responsible for nosocomi-
al infections, which may give a rise to fatal outcomes because of limited therapeutic options. The World 
Health Organization and the Center for Disease Control in Atlanta in the United States unanimous-
ly identified carbapenem-resistant P. aeruginosa as one of the most significant multidrug resistance 
pathogenic bacteria. Old antibiotics such as polymyxin (colistin) are growingly used as a last resort 
treatment for MDR P. aeruginosa(3,4,5).
Multidrug resistance has lead to a renewed interest in polymyxins, colistin and polymyxin B, as ther-
apeutic options for clinically important Gram-negative bacilli(6). The toxicity of such agents was the 
main reason for the low clinical use in early years. Previously, there has been no need for the detailed 
investigation of the microbiological and pharmacological properties of polymyxins since more active 
and efficient alternatives were readily available. These membrane-active drugs have accordingly been 
replaced by newer and more potent antimicrobials(2,7,8). However, enhancing resistance to various anti-
biotics has rendered new drugs unsuccessful against nosocomial pathogens. Thus, exhaustive studies 
on the efficacy, toxicity, and pharmacokinetics of these agents are necessary. In medical and veterinary 
medicine, the broad use of antibiotics has contributed to the development of drug resistance. As a 
result, combination therapy and more successful treatments are being sought for serious infections.
Pharmaceutical products, especially antibiotics, must comply with the quality, efficacy, and reliability 
standards set by competent authorities. In recent decades, the quality and efficacy of generic antibiot-
ics are topics extensively discussed in research communities. Hence, investigation of these antibiotics 
using biological assays is of paramount importance, and commercial products necessarily have to be 
similar to the global composite reference standard(9,10). Although polymyxin B has been available for de-
cades, the pharmacological knowledge of this drug remains considerably limited and constitutes a ma-
jor barrier to its effective use(11). To understand the susceptibility of commonly isolated P. aeruginosa 
to polymyxin in Iran, we investigated the evaluation of in vitro antibacterial activity of polymyxin prod-
ucts, including those frequently cause various infections in Iranian hospitals, against P. aeruginosa.
Materials and methods
Materials
Generic polymyxin products were acquired from local pharmacies approved by Iran Food and Drug 
Administration for the industrial use. The generic drugs applied in this study include Otosporin 
(GlaxoSmithKline, UK), Poly-Mxb (Bharat Serums & Vaccines Ltd., India), and Myxacort (Sina, Iran), 
which their detailed information is available in Table 1. A reference standard, polymyxin B sulfate (CAS 
number 1405-20-5; Sigma-Aldrich, USA), was also used for biological tests.
Table 1. Polymyxin products, pharmaceutical dosage form, and manufacturer
Polymyxin product (code) Presentation Manufacturer
Analytical standard Polymyxin B sulfate, powder Sigma-Aldrich
Generic A Polymyxin B sulphate 10,000 U/mL + Neo-
mycin sulphate 3,400 U/ mL + Hydrocorti-
sone 1.0% w/v
GlaxoSmithKline
Generic B Polymyxin B 500000 IU Bharat Serums & Vaccines Ltd, India
Generic C Polymyxin B sulfate:10’000 U/mL+ Neo-
mycin sulfate: 5 mg/mL + Hydrocortisone: 
10 mg/ML
Sina, Iran
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Bacterial strains
A total of 63 isolates of P. aeruginosa were collected from inpatients in Besat Hospital in Hamadan, Iran 
from June 2019 to September 2019. Conventional biochemical tests, such as oxidase, growth in oxi-
dation fermentation (OF) medium, and pigment production, identified the isolates obtained. The API 
20NE system (bioMérieux, Marcy l’Etoile, France) was then used for the final identification of isolates.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was conducted with the following antibiotics: amoxicillin/clavulan-
ic acid, cefotaxime, ceftriaxone, aztreonam, tetracycline, ceftazidime, and cefepime (30 μg of each), 
colistin, gentamicin, imipenem, and Polymyxin B (10 μg of each), and ciprofloxacin (5 μg). The test was 
accomplished as per the Clinical and Laboratory Standards Institute (CLSI) 2018 guidelines(12).
Potency determination using the disk diffusion (DD) method
All the isolates were tested for in vitro polymyxin B susceptibility using the powder disks made from 
polymyxin B sulfate, Otosporin, Poly-Mxb, and Myxacort products. Sterile blank disks were saturated 
with 20 µl of each stock polymyxin B product. After being dried, the disks were ready for DD test. The 
standard product was utilized to compare commercially available antibiotic disks (polymyxin B; MAST, 
UK)(13).
Determination of minimum inhibitory concentration (MIC)
The susceptibility testing was conducted using the broth microdilution (BMD) method as recommend-
ed by the CLSI guideline(12). Mueller Hinton Broth (MHB; 100 μl) was added to the rows 2-12 of a 96-well 
microtitre plate. Thereafter, 200 μl of the various polymyxin B products was added to row 1 and then 
serially diluted through row 10. No polymyxin B products were added to row 11, which served as a 
growth control. After culturing on the Mueller Hinton Agar plates, P. aeruginosa was incubated at 37 
°C for 18 h. Subsequently, colonies were separately transferred to a test tube. The separated colonies 
were inoculated into the MHB (5 mL), which was then incubated at 35 °C for 4 h. By applying the 0.5 
McFarland standard, the adjustment of the turbidity of an active growing broth culture with a sterile 
broth was accomplished. Then the bacterial suspension was diluted 1:100 using the appropriate broth 
to achieve a final concentration about 5×105 CFU/ml. The bacterial cells (100 μl) was added to each well 
on the panel, resulting in a final volume of 200 μl. The purity of each isolate was checked by adding a 
sample of each isolate to the microtitre panel and inoculating a fresh agar plate. Both the purity plates 
and the microtitre panels were incubated at 35 °C for 16-20 h. In the end, broth microdilution method 
was conducted, and assays were performed by the aid of MHB. The concentrations of polymyxin B (i.e. 
polymyxin B sulfate, Otosporin, Poly-Mxb, and Myxacort products) were in the range of 0.25-1024 μg/μl. 
The microtitre panels were removed from the incubator after 16-20 h and read. Control strains included 
Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853.
Statistical analysis
Chi-square was used to compare the in vitro activity of various polymyxin B products in P. aeruginosa 
isolates and was performed triplicate. SPSS version 16 was applied for statistical analysis. Probabilities 
(p values) less than 0.05 were considered as statistically significant.
Results
The isolates were collected from different infection sites of patients hospitalized in several wards. P. 
aeruginosa isolates were most often recovered from burn wounds (41.26%), blood (20.64%), catheter 
(15.88%), urine (14.29%), and discharges (7.94%). The frequency of antibiotic resistance in the isolates 
of P. aeruginosa is shown in Figure 1. The highest and lowest resistance was observed for ceftriaxone 
(65.07%) and amikacin (33.33%), respectively. Polymyxin B demonstrated significant in vitro antimi-
crobial activity against all the P. aeruginosa isolates, which were susceptible to colistin. In addition, 
99.1% of the isolates were susceptible to polymyxin B. Among the 63 P. aeruginosa isolates, 42 isolates 
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indicated simultaneous resistance to six antibiotics (aztreonam, cefotaxime, amoxicillin-clavulanic 
acid, gentamicin, ceftriaxone, and ceftazidime). Disks made of three types of polymyxin B products 
(Otosporin, Poly-Mxb, and Myxacort) showed similar antibacterial activity compared to the standard 
polymyxin B disk (MAST, UK; Table 2). Wound infection was the main source of polymyxin-resistant P. 
aeruginosa (Figure 2). MICs of polymyxin B products for all P. aeruginosa isolates are shown in Figure 3. 
Otosporin had functional activity against most P. aeruginosa isolates, and seven isolates had a relative-
ly high MIC (≥2 μg/mL). Poly-Mxb and Myxacort had similar activity with otosporin. Polymyxin B sulfate 
compared to other generic drugs, e.g. Poly-Mxb and Myxacort (and otosporin, demonstrated a higher 
MIC50 level (Figure 3).
Table 2. Comparison of the concentration of polymyxin B products in the disks prepared manually with standard 
polymyxin B disk.
StPolymyxin B Polymyxin B 
sulfate
Otosporin Poly-Mxb Myxacort
300 U 30 µg/20µl 300 U/20 µl 50 U/20 µl 310 U/20 µl
Figure 1. Antibiotic resistances pattern of Pseudomonas aeruginosa. No significant difference was seen in antibiotic 
resistances pattern in P. aeruginosa isolates from different sources.
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Figure 2. MIC50 and MIC90 of polymyxin B sulfate for Pseudomonas aeruginosa isolated from different clinical sourc-
es.
Figure 3. Comparative in vitro activity of polymyxin B products against Pseudomonas aeruginosa isolates.
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Discussion
Polymyxins are known to target the outer membrane of Gram-negative bacteria by displacing divalent 
calcium and magnesium ions from the negatively charged phosphate groups of membrane lipids. This 
process causes the destabilization of the lipopolysaccharide (LPS) and the membrane, leading to the 
leakage of cytoplasmic contents and bacterial cell death. Although a clear mechanism of action is not 
known, polymyxins have been suggested to be capable of binding to to endotoxin, which is the lipid 
A portion of the LPS and neutralizes LPS during cell lysis. Polymyxins have bactericidal effect against 
several Gram-negative pathogens such as E. coli, A. baumannii, P. aeruginosa, K. pneumoniae, Entero-
bacter spp., Salmonella spp., and Shigella spp. Until recently, the mechanisms of reported polymyxin 
resistance have been chromosomally mediated that result in LPS modifications, formation of capsules, 
and overexpression of outer membrane protein OprH, thereby conferring resistance in Gram-negative 
bacteria(13,14). In 2015, a plasmid-mediated polymyxin resistance mechanism (MCR-1) was reported in 
Enterobacteriaceae, which is further compromising and threatening the treatment using polymyxin 
antibiotics(15).
Antibiotic resistance is a growing public health problem worldwide, and the resistance pattern of mi-
croorganisms mainly differs in varied communities. Therefore, it is crucial to specifically plan for dimin-
ishing the resistance of antibiotics, particularly those most widely used for treatment(17,18). Studies have 
suggested that polymyxin B is an effective agent for treating P. aeruginosa infections. Polymyxin B has 
long been utilized as a topical agent for the treatment of conjunctivitis, otitis, and infectious surgical 
complications, especially osteomyelitis(19,20). The emergence of polymyxin resistance among P. aerugi-
nosa clinical isolates has recently raised the concern that effective antimicrobial treatment options for 
these isolates can severely be limited in the future.
A comparison of our study results those from similar studies in other countries displays that in vitro 
polymyxin B is highly active against all clinical isolates of P. aeruginosa(21,28). Only for P. aeruginosa iso-
lates, an excellent level of concordance has been found between the two generic polymyxin B products 
(Myxacort and Poly-Mxb) and otosporin. The level of essential agreement achieved for all P. aeruginosa 
isolates from otosporin was more than 90%. For all P. aeruginosa isolates, similar results were obtained 
from the antimicrobial susceptibility test, which was performed by Mast Company.
Our studies uncovered that Myxacort and Poly-Mxb have the same antibacterial potential. Disks made 
from different polymyxin B products seem to have problems interpreting the results due to the combi-
nation of additional compounds with polymyxin. MIC testing was performed using commercially avail-
able polymyxin B sulfate powders. The discrepancy in the relative proportions of the mixture constit-
uents between the powder disks and the producers seems to be due to the additional components in 
the generic polymyxin B compared to polymyxin B sulfate.
The DD test, a simple and an inexpensive method for screening a large number of isolates, is used to 
determine the antimicrobial susceptibility in many clinical laboratories(25). However, the weak and slow 
diffusion of polymyxins through agar is associated with small zones of growth inhibition and significant 
assay variation, negating the use of this method for susceptibility testing. In fact, the predictive accura-
cy of the DD test is unacceptable, and consequently, no reliable correlation of zone diameters with MICs 
has been found in many previous studies. The difficulty in differentiating the inhibition zone diameters 
has been illustrated by Jerke et al.(26) who compared a P. aeruginosa-resistant isolate of 10 mm diameter 
with a susceptible isolate of 11 mm diameter; both isolates were categorized as susceptible with BMD 
MICs of ≤0.25 μg/ml.
At the same time, MICs achieved by the broth microdilution with refined forms of the main constituents 
of polymyxin B were found to be within a log2 dilution of the MICs achieved from the US Pharmacopoeia 
polymyxin B sulfate powder mixture(21). These data implies that the composition of the powder possibly 
does not affect polymyxin susceptibility testing. Broth dilution is a method in which a predetermined 
concentration of the bacterial suspension is tested against different levels of the antimicrobial agent in 
a predetermined liquid medium. For testing polymyxin antimicrobial susceptibility, it is currently the 
only procedure approved by the Clinical and Laboratory Standards Institute (CLSI) and the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST)(5). The broth microdilution method is per-
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formed by a cation-adjusted MHB, twofold dilutions of polymyxin B (ranging from 0.12 to 512 μg/mL), 
and a final bacterial inoculum of 5 ~105 CFU/mL in each well, according to the CLSI guidelines. Broth 
microdilution is recognized as an optimal method and is presently recommended for susceptibility 
testing in the recent document proposed by the joint CLSI-EUCAST Polymyxin Breakpoints Working 
Group(23,27). However, this approach is time-consuming, and antibiotic solutions can cause significant 
errors in manual preparation (if the technique used is unautomated). It is, therefore, unadaptable to 
most clinical microbiology laboratories. Non-reproductive and non-interpretable MIC findings for En-
terobacter species, P. aeruginosa and A. baumannii, have also been reported owing to the presence of 
skip wells, i.e. those that do not show growth, but growth is observed in wells with higher antibiotic 
concentrations(18,23,24). Moreover, some technical issues for testing have been reported using Broth mi-
crodilution method. Polymyxins readily adhere to the plastic trays, leading to decreased antibiotic con-
centrations actually being present in the MHB dispensed in the wells. The addition of a surfactant, such 
as polysorbate 80 (P-80), limits polymyxin adhesion to the BMD panels. It has also been demonstrated 
that it possesses a synergistic effect on polymyxins and has antibacterial activity of its own.Nonethe-
less, CLSI or EUCAST guidelines do not currently recommend using P-80 for polymyxin B susceptibility 
testing by BMD(25).
Antibiotic activities should be tested in vitro and in vivo to confirm their suitability for clinical applica-
tion. Pharmaceutical equivalence or MIC value systems of any generic product is/are invalid require-
ments for equal treatment. In view the fact that MIC breakpoints for Gram-negative and Gram-positive 
bacteria in polymyxin B products (Myxacort, Poly-Mxb, and Otosporin) have not yet been acquired, it 
remains unclear whether the in vitro efficacy of antibacterial drugs predicts the clinical outcome. To 
achieve this goal, all the generic polymyxin B products are required to be checked in vivo. It would be 
better to perform further tests for in vivo use of Myxacort and Poly-Mxb, an activity against different 
species, stability, etc.
Considering the similarity of the national generic polymyxin B product (Myxacort) and the external 
products (Poly-MXb and otosporin), it is rationale to conclude that these products have the same mi-
crobiological actions, as evaluated by DD and MIC tests. We suggest the preparation of antibiotic pow-
der disks in developing countries that can be used in the absence of standard disks in microbiological 
activity. These findings need to be further investigated and confirmed in vivo.
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